Dafinchi AI

United Therapeutics Corporation

UTHR

Healthcare

2w

Financial Performance Summary

Orenitram, Remodulin, and Unituxin also delivered strong performance with double-digit revenue growth.
Remodulin maintained strong demand, achieving a top 5 quarter in total patient shipments.
The company generated nearly $1.5 billion in annual operating cash flow, demonstrating exceptional operating efficiency.
This marks the 12th consecutive quarter of double-digit year-over-year total revenue growth.
Tyvaso DPI achieved record total revenue of $315 million, a 22% increase over Q2 2024, with record patient shipments.
United Therapeutics reported record total revenue of $799 million for Q2 2025, reflecting 12% growth over Q2 2024.

Medpace Holdings, Inc.

MEDP

Healthcare

3w

Financial Performance Summary

Cash flow from operations was $148.5 million, and net days sales outstanding was negative 65 days.
EBITDA for Q2 was $130.5 million, up 16.2% year-over-year, with a margin of 21.6%.
Ending backlog was approximately $2.9 billion, down 1.8% year-over-year.
Net income was $90.3 million, a 2.2% increase from the prior year, with diluted EPS of $3.10.
Net new business awards entering backlog increased 12.6% to $620.5 million, with a book-to-bill ratio of 1.03x.
Revenue for Q2 2025 was $603.3 million, a 14.2% year-over-year increase.
Share repurchases totaled 1.75 million shares for $518.5 million in Q2, with $826.3 million remaining under authorization.

IQVIA Holdings Inc.

IQV

Healthcare

3w

Financial Performance Summary

Adjusted EBITDA increased 2.6% in Q2, with adjusted diluted EPS rising 6.4% to $2.81 year-over-year.
Backlog reached a record $32.1 billion, up 5.1% year-over-year, with next 12 months revenue from backlog at $8.1 billion, up 4.8%.
Contract Sales & Medical Solutions revenue increased 9.3% reported and 6.4% constant currency.
IQVIA reported second quarter 2025 revenue exceeding $4 billion for the first time, growing 5.3% year-over-year on a reported basis and 6.3% excluding COVID-related work.
Issued $2 billion senior notes maturing in 2032.
Net leverage ratio was 3.61x trailing 12-month adjusted EBITDA; free cash flow was $292 million in Q2 after $151 million capex.
R&D Solutions (R&DS) revenue grew 2.5% reported and 1.3% constant currency, with 4.2% growth excluding COVID-related revenues.
Share repurchases totaled over $1 billion in the first half, with $607 million repurchased in Q2 alone.
Technology & Analytics Solutions (TAS) revenue grew 8.9% reported and 6.8% constant currency, driven by double-digit growth in real-world evidence.

Lantheus Holdings, Inc.

LNTH

Healthcare

1w

Financial Performance Summary

Adjusted net income was $110.6 million, down 12.8%, with adjusted EPS of $1.57, also down 12.8%.
Gross profit margin decreased by 80 basis points to 67.6%, mainly due to unfavorable pricing impacts.
Operating cash flow was $87.1 million, up $2.4 million year-over-year; free cash flow increased by $5.6 million to $79.1 million.
Operating expenses increased by 227 basis points to 27.2% of net revenue, reflecting investments in growth initiatives.
Operating profit declined 10.8% to $152.6 million.
Precision Diagnostics revenue increased 3.3% to $115.8 million, driven by DEFINITY sales up 7.5%.
Radiopharmaceutical oncology segment, primarily PYLARIFY, generated $250.6 million in sales, down 8.3%.
Second quarter 2025 consolidated net revenue was $378 million, down 4.1% year-over-year.
The company repurchased $100 million of shares during the quarter and completed the Evergreen acquisition for approximately $226 million net of cash.
U.S. volumes for PYLARIFY increased 2% year-over-year and over 4% sequentially but were below expectations.

Alnylam Pharmaceuticals, Inc.

ALNY

Healthcare

2w

Financial Performance Summary

Alnylam reported total net product revenues of $672 million in Q2 2025, representing 64% year-over-year growth driven by a 77% increase in the TTR franchise.
Cash, cash equivalents, and marketable securities totaled $2.9 billion at quarter-end, up from $2.7 billion at year-end 2024.
Collaboration revenue decreased by $166 million to $61 million due to the modification of the cemdisiran agreement with Regeneron.
Gross margin on product sales was 79%, down from 84% in Q2 2024, mainly due to increased royalties on AMVUTTRA.
Non-GAAP operating income was $95 million, a $42 million decrease compared to last year, mainly due to lower collaboration revenue recognition.
Non-GAAP R&D expenses increased 11% to $274 million, driven by clinical trial expenses for zilebesiran and TRITON-CM studies.
Non-GAAP SG&A expenses increased 26% to $261 million, primarily due to investments supporting the AMVUTTRA ATTR-CM launch.
Royalty revenue increased by $18 million to $40 million, driven by higher Leqvio sales.
The U.S. TTR franchise grew 125% year-over-year, primarily due to the ATTR-CM launch of AMVUTTRA, contributing approximately $150 million in revenue from 1,400 cardiomyopathy patients on therapy.

RDNT

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA reached a quarterly record of $81.2 million, up 12.3% from the prior year, with margin expansion to 16.3% from 15.7%.
Advanced imaging procedures increased to 27.5% of total procedures, with MRI up 6.6%, CT up 5.9%, and PET/CT up 16.2% on a same-center basis.
Cash balance was strong at $833 million with net debt to adjusted EBITDA ratio below 1x, reflecting solid liquidity and leverage management.
Digital Health segment revenue grew 30.9% to $20.7 million, driven by AI-powered breast cancer screening and expanded licensing.
RadNet reported record quarterly revenue of $498.2 million in Q2 2025, an 8.4% increase year-over-year.

Sotera Health Company

SHC

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA increased 9.8% to $151 million with margins expanding 156 basis points to 51.2%.
GAAP net income was $8 million or $0.03 per share, impacted by a $34 million settlement; adjusted EPS improved to $0.20 from $0.19 in Q2 2024.
Nelson Labs revenue declined 3.3% to $57 million but segment income rose 13.9% with margin expansion of over 500 basis points.
Nordion revenue increased 2.9% to $42 million but segment margin declined 145 basis points due to supplier mix timing.
Sotera Health reported Q2 2025 revenues of $294 million, up 6.4% year-over-year, or 6% on a constant currency basis.
Sterigenics revenue grew 10.5% to $195 million driven by volume/mix and pricing gains.

Elevance Health Inc.

ELV

Healthcare

1mo

Financial Performance Summary

Adjusted operating expense ratio improved by 140 basis points to 10.0%.
Benefit expense ratio rose 260 basis points to 88.9%, mainly due to ACA and Medicaid cost pressures.
Carelon Rx revenue grew over 20%, while Carelon Services revenue and operating gain grew over 50%.
Debt-to-capital ratio was 40.8%, with $2 billion returned to investors year-to-date.
Elevance Health reported Q2 2025 GAAP diluted EPS of $7.72 and adjusted EPS of $8.84, consistent with expectations.
Medical membership declined by approximately 200,000 sequentially, primarily from Medicaid and ACA effectuation rates.
Operating cash flow was $2.1 billion for the quarter, with a full-year expectation of $6 billion reflecting revised outlook and working capital items.
Operating revenue increased 14% year-over-year to $49.4 billion, driven by higher premium yields and acquisitions.

Intuitive Surgical, Inc.

ISRG

Healthcare

3w

Financial Performance Summary

Da Vinci procedures increased 17% globally, with U.S. growth led by benign general surgery and international growth led by non-urology procedures.
GAAP net income was $658 million or $1.81 per share, up from $527 million or $1.46 per share last year.
Gross margin declined to 67.9% from 70% last year due to higher facilities costs, product mix, and tariffs.
Instrument and accessory revenue per procedure remained stable at approximately $1,800.
Pro forma operating margin was 39%, and pro forma earnings per share increased 23% to $2.19.
Second quarter revenue grew 21% to $2.44 billion, driven by strong procedure growth and capital placements.
SP procedures grew 88% year-over-year, and Ion procedures grew 52% to approximately 35,000.
System placements totaled 395, including 180 da Vinci 5 systems and 23 SP systems, with strong U.S. capital placements but macro challenges in Japan, China, and Europe.

SIBN

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA was positive $1 million for the quarter, marking the third consecutive quarter of positive adjusted EBITDA.
Gross profit increased by $7.2 million or 22.9% to $38.8 million, with gross margin expanding by 80 basis points to 79.8%.
International revenue was $2.2 million, impacted by later-than-expected regulatory clearance for TORQ in Europe.
Net loss narrowed to $6.2 million or $0.14 per diluted share from $8.9 million or $0.22 per diluted share in the prior year.
Operating expenses rose 10% to $45.8 million, mainly due to growth investments, higher commissions, and elevated G&A spending.
SI-BONE reported worldwide revenue of $48.6 million for Q2 2025, representing 21.7% growth year-over-year.
The company achieved cash flow breakeven in Q2 2025, an important milestone reached ahead of schedule.
Trailing 12-month adjusted EBITDA was positive $3.1 million compared to a loss of $15.4 million in the prior year period.
U.S. revenue, which accounts for 95% of the business, grew 22.8% driven by a 25% increase in procedure volumes.

ABBV

Healthcare

2w

Financial Performance Summary

AbbVie delivered adjusted earnings per share of $2.97, $0.11 above guidance midpoint, with total net revenues of $15.4 billion, exceeding expectations by over $400 million.
Adjusted gross margin was 84.4%, R&D expense 13.7%, SG&A 21%, and operating margin 44.3%, including unfavorable impact from acquired IPR&D expense.
Aesthetics revenues nearly $1.3 billion, down 8% due to economic challenges and lower consumer sentiment.
HUMIRA global sales declined 58.2% due to biosimilar competition.
Neuroscience revenues approximately $2.7 billion, up 24% operationally, led by Vraylar, BOTOX Therapeutic, Ubrelvy, and QULIPTA.
Neuroscience revenues grew double digits, driven by Vraylar, Vyalev, and migraine portfolio.
Oncology revenues nearly $1.7 billion with IMBRUVICA down 9.5%, Venclexta up 8.3%, and early launch of EMRELIS.
Sales growth of 22% from ex-HUMIRA platform driven by strong performance of Skyrizi and Rinvoq, now on pace to deliver over $25 billion combined sales in 2025.